TD Cowen raises target for UCB stock to EUR 340

Published on 10/27/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bimzelx sales were EUR 1.52 billion in HY 2026. UCB stock costs EUR 269.50 on October 27, 2026, down 0.30 percent versus Euronext Brussels close.

Target, sales and dates

On October 23, TD Cowen raised its UCB target from EUR 305.00 to EUR 340.00.
Bimzelx sales reached EUR 1.52 billion in the first half of 2026.
UCB stock costs EUR 269.50 at Lang & Schwarz on October 27, 2026 at 4:49 p.m. CEST, down 0.30 percent versus the Euronext Brussels close of October 26, 2026 at EUR 270.30.
UCB plans to publish full-year 2026 results on February 25, 2027.

UCB, BE0003739530, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) has a fresh analyst target of EUR 340.00 after TD Cowen lifted its target from EUR 305.00 on October 23, 2026, according to Investing.com. The new target is 26.16 percent above the Lang & Schwarz price of EUR 269.50. At Lang & Schwarz, UCB stock was trading at EUR 269.50 on October 27, 2026 at 4:49 p.m. CEST, down 0.30 percent versus the Euronext Brussels close of October 26, 2026 at EUR 270.30.

What does the target imply?

TD Cowen cited a projected EUR 200.00 million beat in Bimzelx consensus estimates and the treatment's efficacy position, according to Investing.com. Its valuation uses a discounted cash flow model based on about 20 times estimated 2028 earnings, while the article said the target could approach EUR 350.00 under a higher multiple.

UCB's updated 2026 outlook is another measurable support for the valuation discussion. The company expects revenue growth in the low twenties at constant exchange rates, up from the low-to-mid-teens range, while adjusted EBITDA growth is expected in the low-to-mid-forties range, according to MarketScreener on October 22, 2026.

6.91 percent below yearly high

The EUR 269.50 Lang & Schwarz price sits within UCB's EUR 197.45 to EUR 289.50 52-week range as of October 27, 2026. It is 6.91 percent below the high and 36.49 percent above the low. The Euronext Brussels quote showed 114,937 shares traded on October 27, 2026.

Valuation and reporting date

UCB had a market capitalization of EUR 51.4 billion and a price-to-earnings ratio of 23.34 on October 27, 2026. The investor page lists Bimzelx sales of EUR 1.52 billion in the first half of 2026, while Cimzia sales reached EUR 954.00 million in the same period, according to UCB.

UCB is scheduled to publish full-year 2026 results and formal 2027 guidance on February 25, 2027, according to MarketScreener. That date gives investors a defined checkpoint for testing whether the upgraded outlook is translating into reported growth.

Comparison with peers

UCB: down 0.30 percent, price-to-earnings ratio 23.34, market capitalization EUR 51.4 billion as of October 27, 2026. AbbVie (NYSE, USD): down 0.11 percent, price-to-earnings ratio 80.73, market capitalization USD 506.5 billion as of October 27, 2026. Amgen (Nasdaq, USD): up 3.25 percent, price-to-earnings ratio 27.77, market capitalization USD 242.1 billion as of October 27, 2026.

The price stays below EUR 289.50

UCB's valuation now combines a EUR 340.00 TD Cowen target with a 2026 outlook calling for revenue growth in the low twenties. The stock remained 6.91 percent below its 52-week high on October 27, 2026.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.